Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Frontiers in Genetics - Switzerland
doi 10.3389/fgene.2020.00349
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
2020English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Management of Adverse Events During Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer

Therapeutic Advances in Medical Oncology
Oncology
2018English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy